Immunofoco
Immunofoco’s iMagic platform uses a fusogen and T-cell-targeting modules for in vivo CAR-T. It identifies CD19 IMV101 in IITs, alongside BCMA IMV102 and CLDN18.2 IMV103. Phase 3 IMC002 is an ex vivo program and does not establish in vivo Phase 3 development.
Corporate information
- Company entity
- Immunofoco
- Headquarters / principal office
- Shenzhen, China (international operations headquarters); Shanghai R&D/operations and Suzhou manufacturing ↗
- Founded
- 2020 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.immunofoco.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Immunofoco’s iMagic platform uses a fusogen and T-cell-targeting modules for in vivo CAR-T. It identifies CD19 IMV101 in IITs, alongside BCMA IMV102 and CLDN18.2 IMV103. Phase 3 IMC002 is an ex vivo program and does not establish in vivo Phase 3 development.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.